Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...

Researchers used mice with nine different genetic backgrounds to identify factors influencing eye aging, paving the way for eye-based diagnostics for neurodegenerative diseases.

Vision changes are an inevitable part of aging, but why are some more susceptible to age-related eye diseases and why do some ...

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

Chitra Kannabiran, PhD, Kallam Anji Reddy Molecular Genetics Laboratory, Hyderabad Eye Research Foundation ... understanding of the genetics of retinitis pigmentosa (RP), a clinically and ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Tebogo 'Mr Tap' Poopedi from Soweto proved that determination knows no limits when he participated in the 36th Dis-Chem Ride for Sight challenge at Boksburg Stadium on February 16.

At a mean of 16.1 days after fever onset, patients experienced initial symptoms including sudden vision loss, visual field ...

Restore Vision Inc., a clinical-stage gene therapy company, specializes in developing transformative gene therapies for inherited retinal disorders. By integrating academic excellence with ...